• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/3/21 1:13:21 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TEVA alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*

                

    TEVA PHARMACEUTICAL INDUSTRIES LTD


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    M8769Q102


    (CUSIP Number)

    December 31, 2020


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. M8769Q102

    1. NAMES OF REPORTING PERSONS

    Wellington Management Group LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 310,793
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 310,793
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    310,793
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.03%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. M8769Q102

    1. NAMES OF REPORTING PERSONS

    Wellington Group Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 310,793
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 310,793
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    310,793
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.03%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. M8769Q102

    1. NAMES OF REPORTING PERSONS

    Wellington Investment Advisors Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 310,793
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 310,793
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    310,793
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.03%
    12. TYPE OF REPORTING PERSON

    HC

    Item 1.
    (a) Name of Issuer
    TEVA PHARMACEUTICAL INDUSTRIES LTD
    (b) Address of Issuer's Principal Executive Offices
    Teva Pharmaceutical Industries Limited
    5 Bazel Street Po B 3190
    Petach Tikva, L3 49131
    Item 2.
    (a) Name of Person Filing
    Wellington Management Group LLP
    Wellington Group Holdings LLP
    Wellington Investment Advisors Holdings LLP
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Wellington Management Group LLP - Massachusetts
    Wellington Group Holdings LLP - Delaware
    Wellington Investment Advisors Holdings LLP - Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    M8769Q102
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [ ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    See the responses to Item 9 on the attached cover pages.
    (b) Percent of Class:
    See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote See the responses to Item 6 on the attached cover pages.
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of See the responses to Item 8 on the attached cover pages.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Exhibit A directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:

    Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    See attached Exhibit A.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021


    Exhibit A

    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

    Wellington Group Holdings LLP – HC
    Wellington Investment Advisors LLP – HC
    Wellington Management Global Holdings, Ltd. - HC

    One or more of the following investment advisers (the “Wellington Investment Advisers”):

    Wellington Management Company LLP – IA
    Wellington Management Canada LLC – IA
    Wellington Management Singapore Pte Ltd – IA
    Wellington Management Hong Kong Ltd – IA
    Wellington Management International Ltd – IA
    Wellington Management Japan Pte Ltd – IA
    Wellington Management Australia Pty Ltd - IA

    The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.


    EXHIBIT B

    JOINT FILING AGREEMENT

    The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of TEVA PHARMACEUTICAL INDUSTRIES LTD is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.


    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 15, 2021

    Get the next $TEVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TEVA

    DatePrice TargetRatingAnalyst
    5/12/2025$23.00Neutral → Overweight
    Analyst
    7/10/2024$20.00Hold → Buy
    Argus
    3/8/2024$14.00Underweight → Neutral
    JP Morgan
    2/12/2024$12.00 → $19.00Neutral → Overweight
    Piper Sandler
    1/23/2024$10.00 → $14.00Hold → Buy
    Jefferies
    1/3/2024$8.00 → $12.00Underweight → Neutral
    Piper Sandler
    12/18/2023$13.00Buy
    HSBC Securities
    11/27/2023$11.00 → $13.00Neutral → Buy
    UBS
    More analyst ratings

    $TEVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

      TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services ("Moody's") has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company's branded franchises, stabilization of the company's generics business, focus on debt reduction and resolution of various legal liabilities https://ratings.moodys.com/ratings-news/443085. "This is a testament to the consistent performance of Teva as a result of the company's Pivot to Growth strategy," said Eli Kalif, Chief Fi

      5/15/25 6:12:25 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

      The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of scheduleTeva launched two new programs to help people around the world access the medicines they need, for a total of nine programs, surpassing its target of eight programs by 2025More than 99% of Teva employees were trained on compliance and ethics, and more than 40% of its significant suppliers were evaluated for sustainability performanceTeva received improved scores for sustainability progress from rating organizations, including its highest score to date from EcoVadisTeva's generic medicines contributed to $39.7 billion in savings for h

      5/12/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

      For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.AUSTEDO® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.AJOVY® – global revenues of $139 million

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Teva Pharma upgraded by Analyst with a new price target

      Analyst upgraded Teva Pharma from Neutral to Overweight and set a new price target of $23.00

      5/12/25 8:18:58 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharma upgraded by Argus with a new price target

      Argus upgraded Teva Pharma from Hold to Buy and set a new price target of $20.00

      7/10/24 8:07:13 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharma upgraded by JP Morgan with a new price target

      JP Morgan upgraded Teva Pharma from Underweight to Neutral and set a new price target of $14.00

      3/8/24 8:21:02 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Teva Pharmaceutical Industries Limited

      10-Q - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      5/7/25 4:06:08 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      5/7/25 7:00:13 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Teva Pharmaceutical Industries Limited

      DEFA14A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      4/9/25 4:12:16 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • See "Remarks" Sabag Mark sold $6,097,304 worth of Ordinary Shares (337,915 units at $18.04), decreasing direct ownership by 69% to 150,996 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      5/12/25 4:00:58 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Lippman Evan

      3 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      4/7/25 4:01:07 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Weiss Amir converted options into 3,566 units of Ordinary Shares, increasing direct ownership by 13% to 30,250 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      3/7/25 4:29:10 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

      5/15/24 8:15:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha

      11/7/23 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Announces Changes to Executive Management Team

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva's U.S. Commercial Business. "On behalf of the Teva Board of Directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with the company," said Richard Francis, Teva's President, and Chief Executive Officer, "I am pleased to announce the appointment of Chris Fox to this critical role. Chris is a h

      9/28/23 4:05:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

      SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      11/12/24 10:34:14 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Teva Pharmaceutical Industries Limited (Amendment)

      SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      4/9/24 10:26:26 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

      SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      2/1/24 8:03:56 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    Financials

    Live finance-specific insights

    See more
    • Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

      For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.AUSTEDO® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.AJOVY® – global revenues of $139 million

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

      TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on Thursday, May 29, 2025 to discuss the acceleration phase of its strategy and portfolio priorities. The event will take place in New York, N.Y. Presentations will begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. Richard Francis, Teva's President and CEO, along with other members of the executive management team will discuss an update on the strategy and key priorities focusing on growth and innovation. Due to limited capacity, in-person attendance is by invitation only. Analysts a

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

      TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 hou

      3/27/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care